Seeking Alpha

MannKind Corporation (MNKD)

  • Fri, Mar. 6, 5:42 PM
    • Top gainers, as of 5:15 p.m.: CRIS +13.4%. NG +6.1%. EXK +4.9%. MNKD +4%. SM +3.9%.
    • Top losers, as of 5:15 p.m.: WBAI -6.2%. VEEV -2.1%. GTN -2.1%. RIGL -1.7%. EVTC -1.5%.
  • Tue, Mar. 3, 11:46 AM
    • As Ben Levisohn reports, Goldman Sachs analyst Jay Olson downgraded MannKind (MNKD -9.6%) after he revised his valuation model to include net discounts to Afrezza of 40% instead of 20% in light of the downward price pressure from payers to other diabetes product makers.
    • He cites the recent launches of Boehringer Ingelheim's Jardiance (empagliflozin) tablets and Eli Lilly's (LLY -1%) Trulicity (dulaglutide injection) that came in 75% below his Q4 estimates. Afrezza's launch trajectory based on script data, albeit early stage, is also falling short of expectations.
    • Mr. Olson has lowered his 2025 sales projection 50% for Afrezza to $1B from $2B and reduced EPS estimates from 2017 onward. He believes that MannKind will achieve the sales targets required to capture $925M in milestones from commercial partner Sanofi (SNY -0.1%), however.
    • His $3 price target leaves a 50% downside from the current price.
    • Previously: MannKind off 10% premarket on Goldman downgrade (March 3)
  • Tue, Mar. 3, 9:24 AM
    • MannKind (NASDAQ:MNKD) is off 10% premarket on robust volume in response to Goldman Sachs' downgrade from Neutral to Sell with a revised price target of $3 from $6. Yesterday's close was $6.64.
  • Tue, Mar. 3, 9:16 AM
  • Tue, Feb. 24, 9:25 AM
    • Longs are finally getting a reprieve with recent IPO Second Sight Medical Products (NASDAQ:EYES). Shares are up 17% premarket on good volume in response to its announcement that all three centers approved to implant the Argus II Retinal Prosthesis System (Argus II) in France have successfully completed their first procedures in patients with retinitis pigmentosa (RP).
    • The French Government is paying the bill for the device and surgery under its Forfait Innovation program which allows early access to the product to 30 patients with advanced RP, an inherited disease that frequently results in complete blindness. It affects ~24K people in France and ~167K Europeans.
    • Second Sight is another medical company started by serial entrepreneur Al Mann, whose track record includes Advanced Bionics, MiniMed and MannKind (NASDAQ:MNKD). It has had an inauspicious debut, however. It peaked at $24.02 on November 20, the day after its IPO at $9 on the 19th. It then sold off hard, bottoming at $8.05 on January 26.
    | 1 Comment
  • Mon, Feb. 9, 5:37 PM
  • Oct. 30, 2014, 3:31 PM
    • MannKind (MNKD -0.7%) is "massively overvalued" and should ultimately fall to $1 per share, says Tourbilliion Capital's Jason Karp in his quarterly letter, according to Bloomberg.
    • The headline was enough to knock the stock about 2% from its session high, but it's since recovered a few cents.
    • Karp previously on MannKind: "Only in a frothy, retail-driven (and now Tweet-driven) market can a stock like MannKind exist with a $4.3B valuation and in our view no clear prospects of revenue."
  • Aug. 12, 2014, 12:45 PM
  • Aug. 11, 2014, 9:16 AM
    | 1 Comment
  • Aug. 11, 2014, 9:02 AM
    • MannKind (NASDAQ:MNKD): Q2 EPS of -$0.19 misses by $0.07.
    • Shares +19% PM.
    • Press Release
  • Aug. 11, 2014, 7:01 AM
  • Jun. 30, 2014, 9:06 AM
    | Comment!
  • Jun. 30, 2014, 7:07 AM
    • Shares of MannKind (MNKD) are up 19% premarket on healthy volume as investors get ready for the first full day of trading after the FDA announced its approval of Afrezza on Friday. Shares initially sold off but recovered a good bit of the down move. The closing price was $10.00 out of a range of $8.20 - 11.11 on turnover of 39.7M shares (4x normal volume).
  • Jun. 27, 2014, 5:36 PM
  • Jun. 4, 2014, 12:16 PM
    • Shares of MannKind (MNKD +6.3%) are up again today on increased volume. Prices have now increased ~168% from the March 31 low of $3.80. The pre-PDUFA (July 15) run-up is being goosed by an expected announcement of a marketing partner.
    • This might be a superb time for profit-taking, however. Prices are extended 35% over the 10-week EMA and money flow is tepid. In addition, the number of mutual funds with positions has dropped to 146 from 152 a year earlier. This is a clear signal for retail investors.
  • Apr. 7, 2014, 9:10 AM
    | Comment!
Visit Seeking Alpha's
MNKD vs. ETF Alternatives
Company Description
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.
Sector: Healthcare
Industry: Biotechnology
Country: United States